China ramped up its short-term cash injection into the banking system to the highest since January this week https://t.co/Raw0q2FqxN ...

Canary Capital files for first staked Injective ETF in the US https://t.co/Xwxwj2wZrF ...

Core Viewpoint - Top Wealth Group Holding Limited has entered into a memorandum of understanding with Jilin Xiuzheng Agriculture and Animal Husbandry Technology Co., Ltd. for a proposed injection of animal-related pharmaceutical products, foods, and supplements business [1][3]. Company Overview - Top Wealth Group Holding Limited is a holding company incorporated in the Cayman Islands, specializing in supplying premium-class sturgeon caviar and operates through its subsidiary in Hong Kong [5]. - The company’s caviar products are endorsed with CITES permits and are sold under private labels as well as its own brand, "Imperial Cristal Caviar," which has seen significant sales growth since its launch [5]. Industry Overview - Jilin Xiuzheng, a member of Xiuzheng Group, specializes in the development and operation of animal-related pharmaceutical products, foods, and supplements [2]. - Xiuzheng Group is recognized as the second largest privately-owned pharmaceutical group in China, achieving sales revenue of RMB67.7 billion in 2024 [2]. Proposed Transaction Details - The MOU outlines that Jilin Xiuzheng will inject its animal-related business, trademarks, copyrights, manufacturing facilities, and distribution rights into Top Wealth in exchange for majority control and voting power [3]. - Following the transaction, Jilin Xiuzheng will have the authority to nominate directors and appoint senior management, while the existing caviar business will continue to be managed by Top Wealth's current team [3]. Market Opportunity - The pet market in China is rapidly growing, with a market size that increased from RMB97.8 billion in 2015 to RMB592.8 billion in 2023, and is projected to reach RMB811.4 billion by 2025 [4]. - The CEO of Top Wealth emphasized the importance of this step to enter the luxury pet market, which presents significant business opportunities as families become wealthier and spend more on pets [4].

$200 BILLION IN CAPITAL WILL ENTER THE MARKET IN Q4 2025 🚨If you think the current rally is great, you don’t know what’s about to come.US banking regulators have proposed changes to the Enhanced Supplementary Leverage Ratio.These changes will relax capital buffer requirements for US banks.As per some estimates, this would unlock $200B+ in liquidity.It’s expected to happen by Q3 end, which is the exact timeframe for rate cuts.Imagine COVID-type liquidity injection + rate cuts happening together.The markets w ...

[Music] For a long time, I've always thought of as life as a puzzle, but a very special kind of puzzle. A puzzle where we can't see a picture in the box. And why do I say this.So, when we start life, like we're basically just learning new things. We're taking in information from the world. We're seeing the things that we like and the things that we don't like and then we somewhere along the way we come up with our personality or as I would say our way of interacting with the world.So why did I even come up ...

Core Insights - SeaStar Medical Holding Corporation has expanded its QUELIMMUNE therapy user base by adding a recognized Texas-based children's hospital, which is significant for treating pediatric patients with ultra-rare Acute Kidney Injury (AKI) [1][5] - The QUELIMMUNE therapy was approved by the FDA in 2024 under a Humanitarian Device Exemption to address life-threatening AKI due to sepsis or septic conditions [1][5] - The SAVE Surveillance Registry has been established to monitor safety and outcomes for pediatric patients treated with QUELIMMUNE compared to standard care, with early data analysis expected to be presented at an upcoming medical conference [2][3] Company Developments - SeaStar Medical is making progress in introducing QUELIMMUNE to top children's hospitals in the U.S. and is collecting significant data on its performance through the SAVE Surveillance Registry [3] - The company is conducting the NEUTRALIZE-AKI pivotal trial, which is evaluating the safety and efficacy of the Selective Cytopheretic Device (SCD) therapy in adults with AKI, with 119 out of 200 planned subjects enrolled [3][9] - SeaStar Medical has received FDA Breakthrough Device Designation for QUELIMMUNE and five other indications, which may facilitate faster approval and better reimbursement dynamics [11] Clinical Outcomes - Data from clinical studies indicate a 77% survival rate for patients treated with QUELIMMUNE, representing a 50% reduction in loss of life compared to historical data, with 87.5% of survivors achieving normal kidney function by Day 60 post-ICU discharge [7] - The NEUTRALIZE-AKI trial's primary endpoint includes a composite of 90-day mortality or dialysis dependency, with secondary endpoints assessing various health outcomes [9] Industry Context - AKI is characterized by a sudden loss of kidney function and can lead to severe complications, including multi-organ dysfunction and increased healthcare costs due to prolonged ICU stays and reliance on dialysis [4] - The QUELIMMUNE therapy is specifically designed for pediatric patients weighing 10 kilograms or more who are on antibiotics and receiving Renal Replacement Therapy in the ICU [5][10] - SeaStar Medical's SCD therapy aims to modulate the immune response to prevent destructive hyperinflammation, which is critical for improving outcomes in patients with AKI and other related conditions [10]

There were antivaccine lawyers in the room that you could kind of overhear talking about something called the vaccine um uh injury compensation program, which is this program that it's like vaccine court. It's how people um get claims for the very rare vaccine injuries that do happen. Those that court has been sort of flooded with people who've been turned away and their cases dismissed, many of whom testified today as a witness.Um but what was it like in there. It was super sad. Yeah, it was a bunch of peo ...

Tracy Bowman is 17 years old. She has an older brother named Jamal who's a track star destined to run at Baylor University, a baby sister, and a beautiful protective mother. Tracy has her own column dedicated to racial justice in her school newspaper.Her friend Tasha always makes her laugh. She's considering dating her friend Dean. Tracy is a normal teenager, but she's dealt with something extraordinary painful, the wrongful conviction of her father.And then the same thing happens to her brother. When the u ...

I think that you'd have to find a way to have more by weeks, more time spread out because um I mean you've seen the amount of injuries that have kind of piled up there at the end of of seasons and you want to have the best players playing in the biggest games and um so if there if there were a way to get to 18 games I'm not a I'm not a big fan of it but if there were a way I think you got to add some by-weeks in there to give uh more time for guys bodies. ...

In the meantime, going to follow some significant developments today in the ongoing legal fight over the Trump administration's attempt to end birthright citizenship. A federal judge in New Hampshire issued a preliminary injunction today, temporarily blocking President Trump's executive order ending birthright citizenship. The judge also granted classaction status to a lawsuit seeking to protect babies who would be denied birthright citizenship by the administration.Joining me now is NBC News senior Homelan ...